收藏切换
The current situation, problems and optimization countermeasures of the basic medical insurance treatment of orphan drugs in China
收藏切换
Longhao MA1, Ye CHEN1, 2, Jinxi DING1, 2, *
World Clinical Drug | 2024, 45(11) : 1125 - 1131
Less
收藏切换
World Clinical Drug | 2024, 45(11): 1125-1131
• Topic •
The current situation, problems and optimization countermeasures of the basic medical insurance treatment of orphan drugs in China
Full
Longhao MA1, Ye CHEN1, 2, Jinxi DING1, 2, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2024-11-10 doi: 10.13683/j.wph.2024.11.003
Outline
收藏切换
Objective

To evaluate the current medical insurance coverage of orphan drugs in China, sort out the reimbursement policies and treatment status of rare disease patients, and provide reference for improving the medical insurance treatment of rare disease patients in China.

Methods

The number of orphan drugs included in the National Reimbursement Drug List in 2023 was counted. The medical insurance reimbursement policies in 31 provincial capitals (excluding Hong Kong, Macao and Taiwan) were collected, and the status of medical insurance treatment for rare disease patients was evaluated by simulated calculation of Recombinant Human Coagulation Factor VIIa for Injection and Efgartigimod Alfa Injection.

Results

The coverage rates of medical insurance for rare diseases and medical insurance for drugs were 68.42% and 69.88%, respectively. On the whole, the medical insurance reimbursement for rare diseases patients was insufficient, and the proportion of personal self-sufficiency of general outpatients even reached more than 90%.

Conclusion

It is recommended that the we should increase the access of orphan drugs to medical insurance. Each province exploring and implementing the one-way payment policy for orphan drugs. At the municipal level, incorporating more rare diseases into the category of special diseases in outpatient clinics, to improve the level of protection and establish a multi-level security mechanism.

rare diseases  /  national basic medical insurance  /  reimbursement treatment  /  reimbursement policy
马龙浩, 陈烨, 丁锦希. 我国罕见病药物基本医保待遇现状、问题及优化对策. 世界临床药物, 2024 , 45 (11) : 1125 -1131 . DOI: 10.13683/j.wph.2024.11.003
Longhao MA, Ye CHEN, Jinxi DING. The current situation, problems and optimization countermeasures of the basic medical insurance treatment of orphan drugs in China[J]. World Clinical Drug, 2024 , 45 (11) : 1125 -1131 . DOI: 10.13683/j.wph.2024.11.003
Year 2024 volume 45 Issue 11
16
5
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.11.003
  • Receive Date:2024-08-15
  • Online Date:2026-11-17
  • Published:2024-11-10
Article Data
Affiliations
History
  • Received:2024-08-15
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.11.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT